BDTX — Q2 2026 Financial Report Analysis

Spending on the old trial falls as the new one starts: Q2 2026 net loss narrows to $9.9 million

Black Diamond Therapeutics is a clinical-stage cancer-drug developer: it has no product on sale, so its quarterly results are about how much it spends, what that money buys in clinical trials, and how long its cash lasts. In the second quarter of 2026 (the three months to June 30), it spent $12.1 million running the business, down from $13.4 million a year earlier. The net loss narrowed to $9.9 million ($0.17 a share) from $10.6 million ($0.19). The lower total hides a change in where the money goes. Spending on its Phase 2 lung-cancer trial of silevertinib fell by $3.3 million as that study wound down. Start-up costs for a new randomized glioblastoma (brain cancer) trial added $2.6 million, and that trial dosed its first patient in May.

At a glance

• $110.5 million in cash and investments at June 30, down $7.8 million in the quarter. Management says this funds operations "into the second half of 2028", about two years.
• R&D down 20.7% to $7.4 million. This is a shift between trials, not a cutback: glioblastoma-trial spending rose from $1.4 million in Q1 to $2.6 million in Q2, and total R&D was up 5.6% on Q1.
• No revenue this quarter or the same quarter last year. The company's only revenue to date came from licensing deals, most recently a $70.0 million upfront payment from Servier in March 2025. That payment is why the first half of 2025 showed a $46.0 million profit and the first half of 2026 shows an $18.9 million loss.

Key figures

Figures from the company's Form 10-Q for the quarter ended June 30, 2026. "Operating cash burn" is the net cash used to run the business (the cash-flow statement's operating activities line) and leaves out buying and selling investments.

Takeaway: The quarter's lower loss is a timing effect, not a cheaper company. The finished lung-cancer study is costing less, and the 150-patient glioblastoma trial that replaces it is only starting to ramp. Management itself expects expenses to "increase substantially". The roughly $3 million a month the company is burning now is a low point. The question that matters is whether $110.5 million gets silevertinib to its next big readout (an interim glioblastoma result expected in the first half of 2028) with money to spare.

Where the R&D money went

The 10-Q splits research and development (R&D) spending by program. That makes the shift easy to see:

The company attributes the lung-cancer decline to "the progression of our Phase 2 clinical trial for silevertinib in NSCLC". The glioblastoma increase is "start up activities" for the new trial. Facilities costs halved because the company sublet the remaining floor of its Cambridge, Massachusetts office in December 2025. G&A (general and administrative: the overhead of running a public company) rose $0.6 million, which the filing puts down mainly to "higher IP-related costs", meaning patent and intellectual-property work.

The science the money is buying

Silevertinib is a pill that blocks EGFR, a protein that drives tumor growth when it is mutated. It is designed to reach the brain, where lung cancer often spreads. The quarter's main news was clinical:

• Frontline lung cancer data (ASCO, May 30, 2026). In 43 previously untreated patients with less common ("non-classical") EGFR mutations, preliminary median progression-free survival was 15.2 months at a median follow-up of 11.2 months. Progression-free survival is how long patients lived before the cancer grew. The overall response rate was 60%. Among the 7 patients with measurable brain tumors, the brain response rate was 86%. Twenty-three of the 43 patients were still on the drug at the data cutoff, and none developed new brain metastases. After dose reductions, serious (Grade 3 or higher) drug-related side effects fell to 28%. The company picked 150 mg once daily as the dose for a pivotal (approval-enabling) trial. These are single-arm results with no comparison group, and the survival figure is still preliminary: the upper bound of its confidence interval has not yet been reached.
• Glioblastoma trial under way. After FDA feedback on the design in January 2026, the company started a randomized Phase 2 trial in newly diagnosed patients whose tumors carry the EGFRvIII mutation and lack a marker (MGMT methylation) that predicts response to standard chemotherapy. About 150 patients will receive the standard chemo drug temozolomide, either alone or with silevertinib. An interim progression-free-survival analysis is expected in the first half of 2028.
• Partnering. The company says it is "continuing to explore potential partnership opportunities to advance silevertinib into pivotal development". In other words, it does not plan to fund a lung-cancer pivotal trial from its current cash alone.

What the headline numbers hide

• Cash burn matches the loss closely. Six-month operating cash outflow was $18.2 million against an $18.9 million net loss. The gap comes from $3.0 million of stock-based pay and $1.1 million of non-cash rent (accounting costs that use no cash), offset by working-capital movements and lease payments. The reported loss is a fair guide to cash spent.
• Year-to-date comparisons are distorted. The first half of 2025 included the one-off $70.0 million Servier licensing payment. So the swing from a $46.0 million profit to an $18.9 million loss says nothing about the underlying business. The quarter-on-quarter comparison is cleaner: no revenue in either quarter of 2026 or in Q2 2025.
• Other income is propping up the bottom line, and some of it is shrinking. The $2.2 million of other income cut the quarter's loss by about 18%. Interest income fell 17.5% to $0.9 million as the cash pile shrank. Sublease income was $1.06 million in the quarter. The original New York sublease ended June 30, but a new sublease of the same space started July 1 and runs to at least June 2028, so this income does not simply disappear. The filing does not give the new rent.
• The runway guidance already assumes higher spending. At the first half's operating burn of about $3.0 million a month, $110.5 million would last roughly three years. Management's "second half of 2028" is shorter than that, which means it plans for costs to rise as the glioblastoma trial enrolls. That is a sensible reading, but it leaves only a few months between the expected interim glioblastoma readout and the end of the stated runway.
• No new shares were sold this half. Financing cash flow was just $32,000, from employee option exercises. Shares outstanding rose only 0.3 million to 57.4 million. The company has an at-the-market facility (a program that lets it sell new shares gradually on the open market) with up to $150 million of capacity, so dilution remains available whenever management chooses to use it. The company has no debt.

What to watch next

• Q3 2026 R&D: glioblastoma-trial costs should keep rising as patients enroll. A quarter in which total R&D jumps toward or above $9 million would confirm the ramp the runway guidance implies.
• A silevertinib partnership for pivotal lung-cancer development. This is the clearest route to funding that trial without large share sales.
• Servier milestones: Black Diamond is eligible for up to $710.0 million in milestone payments plus royalties on BDTX-4933, the drug it licensed to Servier. Any milestone would be non-dilutive cash (cash that does not require issuing shares), but none was recorded in the first half of 2026.
• Updated frontline lung-cancer data: the 15.2-month progression-free survival estimate is preliminary. More follow-up will show whether it holds.

Our read: the company is spending carefully and has two years of funding. But this quarter's lower loss reflects the gap between two trials, not a lasting cost level. Expect losses to widen from here, and a financing or partnering decision to come well before the 2028 glioblastoma readout.